Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.37 |
| ▸ | HTR2A | P28223 | 11/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | AGER | Q15109 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818055 | 0.81 | HTR2C (0.56) | HTR2CHTR2AHTR2BCYP1A2 | |
| SCHEMBL24110212 | 0.81 | NTRK1 (0.39) | HTR2CHTR2ASLC2A1HTR2B | |
| SCHEMBL25295071 | 0.81 | NTRK1 (0.39) | HTR2CHTR2ASLC2A1HTR2B | |
| SCHEMBL25818024 | 0.79 | HTR2C (0.37) | HTR2CHTR2ASLC2A1HPGDAGER | |
| SCHEMBL17463068 | 0.75 | CYP1A2 (0.36) | HPGDLMNAHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL25818070 | 0.75 | HTR2C (0.42) | HTR2CHTR2AHPGDHTR2BCYP1A2 | |
| SCHEMBL16302770 | 0.72 | EGFR (0.37) | HPGDLMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL24026926 | 0.71 | CDK4 (0.53) | HTR2CHTR2AHPGDAGERLMNA | |
| SCHEMBL25818091 | 0.71 | CDK4 (0.53) | HTR2CHTR2AHPGDAGERLMNA | |
| SCHEMBL25296623 | 0.70 | HTR2C (0.45) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885HTR2A 10/4885SLC2A1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.